{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:03:20Z","timestamp":1777935800029,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.7759\/cureus.108119","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:09:17Z","timestamp":1777691357000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Adverse Event Reporting of Asparaginase-Containing Induction Regimens in Pediatric Acute Lymphoblastic Leukemia Using the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.7759","author":[{"given":"Toru","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1542649","article-title":"Analysis of global trends in acute lymphoblastic leukemia in children aged 0-5 years from 1990 to 2021","volume":"13","author":"Ding F","year":"2025","unstructured":"Ding F, Deng L, Xiong J, Cheng Z, Xu J. Analysis of global trends in acute lymphoblastic leukemia in children aged 0-5 years from 1990 to 2021. Front Pediatr. 2025, 13:1542649. 10.3389\/fped.2025.1542649","journal-title":"Front Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111356","article-title":"Global, regional, and national burden of acute lymphoblastic leukemia in children: epidemiological trends analysis from 1990 to 2021","volume":"27","author":"Hu Y","year":"2024","unstructured":"Hu Y, Liu Y, Fu J, Liu Y, Wang H, Song Y. Global, regional, and national burden of acute lymphoblastic leukemia in children: epidemiological trends analysis from 1990 to 2021. iScience. 2024, 27:111356. 10.1016\/j.isci.2024.111356","journal-title":"iScience"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.46989\/001c.117026","article-title":"How I treat newly diagnosed acute lymphoblastic leukemia","volume":"6","author":"Sebastian G","year":"2024","unstructured":"Sebastian G. How I treat newly diagnosed acute lymphoblastic leukemia. Clin Hematol Int. 2024, 6:51-61. 10.46989\/001c.117026","journal-title":"Clin Hematol Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13517","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"93","author":"Tucci F","year":"2008","unstructured":"Tucci F, Aric\u00f2 M. Treatment of pediatric acute lymphoblastic leukemia. Haematologica. 2008, 93:1124-8. 10.3324\/haematol.13517","journal-title":"Haematologica"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2001.0243","article-title":"Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines","volume":"27","author":"Ronghe M","year":"2001","unstructured":"Ronghe M, Burke GA, Lowis SP, Estlin EJ. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treat Rev. 2001, 27:327-37. 10.1053\/ctrv.2001.0243","journal-title":"Cancer Treat Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui CH","year":"2013","unstructured":"Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013, 50:185-96. 10.1053\/j.seminhematol.2013.06.007","journal-title":"Semin Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S106810","article-title":"Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia","volume":"10","author":"Koprivnikar J","year":"2017","unstructured":"Koprivnikar J, McCloskey J, Faderl S. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia. Onco Targets Ther. 2017, 10:1413-22. 10.2147\/OTT.S106810","journal-title":"Onco Targets Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya N","year":"2016","unstructured":"Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016, 57:748-57. 10.3109\/10428194.2015.1101098","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow K","year":"2021","unstructured":"Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021, 21:725-33. 10.1016\/j.clml.2021.07.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194419","article-title":"L-asparaginase toxicity in the treatment of children and adolescents with acute lymphoblastic leukemia","volume":"10","author":"Schmidt MP","year":"2021","unstructured":"Schmidt MP, Ivanov AV, Coriu D, Miron IC. L-asparaginase toxicity in the treatment of children and adolescents with acute lymphoblastic leukemia. J Clin Med. 2021, 10:4419. 10.3390\/jcm10194419","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2024.03.001","article-title":"Peg-asparaginase associated toxicities in children with acute lymphoblastic leukemia: a single-center cross-sectional study","volume":"9","author":"Awwad S","year":"2024","unstructured":"Awwad S, Alnasr RA, Almanjomi F, Al Sultan M, Howaidi J, Almotairi M, AlFayyad I. Peg-asparaginase associated toxicities in children with acute lymphoblastic leukemia: a single-center cross-sectional study. Pediatr Hematol Oncol J. 2024, 9:54-62. 10.1016\/j.phoj.2024.03.001","journal-title":"Pediatr Hematol Oncol J"},{"key":"ref12","unstructured":"FDA Adverse Event Monitoring System (AEMS) quarterly data extract files. (2026). Accessed. January 31, 2026: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol EI","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, et al.. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015, 12:e1001885. 10.1371\/journal.pmed.1001885","journal-title":"PLoS Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee","year":"2016","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016, 25:2-10. 10.1002\/pds.3891","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.052","article-title":"Treatment of adolescent and young adults with acute lymphoblastic leukemia","volume":"6","author":"Ribera JM","year":"2014","unstructured":"Ribera JM, Ribera J, Genesc\u00e0 E. Treatment of adolescent and young adults with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014, 6:e2014052. 10.4084\/MJHID.2014.052","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720903531","article-title":"Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population","volume":"11","author":"Carobolante F","year":"2020","unstructured":"Carobolante F, Chiaretti S, Skert C, Bassan R. Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Ther Adv Hematol. 2020, 11:10.1177\/2040620720903531","journal-title":"Ther Adv Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81260","article-title":"Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System","volume":"17","author":"Ogura T","year":"2025","unstructured":"Ogura T, Shiraishi C. Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System. Cureus. 2025, 17:e81260. 10.7759\/cureus.81260","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81912","article-title":"Comparison of adverse events among angiotensin receptor blockers in hypertension using the United States Food and Drug Administration Adverse Event Reporting System","volume":"17","author":"Ogura T","year":"2025","unstructured":"Ogura T, Shiraishi C. Comparison of adverse events among angiotensin receptor blockers in hypertension using the United States Food and Drug Administration Adverse Event Reporting System. Cureus. 2025, 17:e81912. 10.7759\/cureus.81912","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike H","year":"2003","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 2003, 19:716-23. 10.1109\/TAC.1974.1100705","journal-title":"IEEE Trans Autom Control"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract15110211","article-title":"Asparaginase hypersensitivity reactions in NK\/T-cell lymphomas","volume":"15","author":"Varela Gonzalez-Aller J","year":"2025","unstructured":"Varela Gonzalez-Aller J, Nadal P, Ca\u00f1izares S, et al.. Asparaginase hypersensitivity reactions in NK\/T-cell lymphomas. Clin Pract. 2025, 15:211. 10.3390\/clinpract15110211","journal-title":"Clin Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA Adverse Event Reporting System Database and its impact on signal strength","volume":"56","author":"Neha R","year":"2021","unstructured":"Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of notoriety bias in FDA Adverse Event Reporting System Database and its impact on signal strength. Hosp Pharm. 2021, 56:152-8. 10.1177\/0018578719882323","journal-title":"Hosp Pharm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell NR","year":"2004","unstructured":"Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004, 24:743-9. 10.1592\/phco.24.8.743.36068","journal-title":"Pharmacotherapy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin B","year":"2015","unstructured":"Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015, 56:2273-80. 10.3109\/10428194.2014.1003056","journal-title":"Leuk Lymphoma"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000530655","article-title":"Vincristine-induced seizure from drug interactions: a case report and review of literature","volume":"16","author":"Heidari S","year":"2023","unstructured":"Heidari S, Panahishokouh M, Babakhani D, et al.. Vincristine-induced seizure from drug interactions: a case report and review of literature. Case Rep Oncol. 2023, 16:363-71. 10.1159\/000530655","journal-title":"Case Rep Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.1","article-title":"Corticosteroids in brain cancer patients: benefits and pitfalls","volume":"4","author":"Dietrich J","year":"2011","unstructured":"Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011, 4:233-42. 10.1586\/ecp.11.1","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19610","article-title":"Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy\u2014an observational Ponte di Legno Toxicity Working Group study","volume":"205","author":"Anastasopoulou S","year":"2024","unstructured":"Anastasopoulou S, Swann G, Andres-Jensen L, et al.. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy\u2014an observational Ponte di Legno Toxicity Working Group study. Br J Haematol. 2024, 205:1450-9. 10.1111\/bjh.19610","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss I","year":"2016","unstructured":"Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016, 96:375-80. 10.1111\/ejh.12600","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ TN","year":"2018","unstructured":"Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018, 24:299-308. 10.1177\/1078155217701291","journal-title":"J Oncol Pharm Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1852471","article-title":"Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia","volume":"62","author":"West ZE","year":"2021","unstructured":"West ZE, Castellino SM, Monroe C, Thomas AS, McCracken C, Miller TP. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2021, 62:899-908. 10.1080\/10428194.2020.1852471","journal-title":"Leuk Lymphoma"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479274-comparative-adverse-event-reporting-of-asparaginase-containing-induction-regimens-in-pediatric-acute-lymphoblastic-leukemia-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:09:22Z","timestamp":1777691362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479274-comparative-adverse-event-reporting-of-asparaginase-containing-induction-regimens-in-pediatric-acute-lymphoblastic-leukemia-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.108119","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}